We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.27B
AUM Growth
+$432M
Cap. Flow
+$259M
Cap. Flow %
7.92%
Top 10 Hldgs %
37.03%
Holding
113
New
28
Increased
27
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$111M
2
MYGN icon
Myriad Genetics
MYGN
+$77.2M
3
BAX icon
Baxter International
BAX
+$36.4M
4
BFLY icon
Butterfly Network
BFLY
+$36.2M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$35.7M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$52.7M
2
IRTC icon
iRhythm Holdings
IRTC
+$40.6M
3
PEN icon
Penumbra
PEN
+$32.4M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
26
AstraZeneca
AZN
$242B
$40.3M 1.23%
405,200
-142,100
-26% -$14.3M
DHR icon
27
Danaher
DHR
$139B
$39.5M 1.21%
198,178
+5,006
+3% +$1.02M
BAX icon
28
Baxter International
BAX
$14.3B
$38.7M 1.18%
+458,476
New +$36.4M
AERI
29
DELISTED
Aerie Pharmaceuticals
AERI
$37M 1.13%
2,067,684
-159,927
-7% -$2.76M
NVAX icon
30
Novavax
NVAX
$1.25B
$36.4M 1.11%
200,745
-15,163
-7% -$3.02M
CYTK icon
31
Cytokinetics
CYTK
$10.7B
$35.7M 1.09%
1,536,373
+565,222
+58% +$12.1M
CNC icon
32
Centene
CNC
$31.9B
$34.1M 1.04%
533,667
+205,188
+62% +$12.7M
HRTX icon
33
Heron Therapeutics
HRTX
$102M
$34M 1.04%
2,098,578
+87,101
+4% +$1.55M
ACAD icon
34
Acadia Pharmaceuticals
ACAD
$4.48B
$33.6M 1.03%
1,302,129
+42,655
+3% +$1.88M
JNCE
35
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$33.5M 1.02%
+3,262,833
New +$35.7M
CANO
36
DELISTED
Cano Health, Inc.
CANO
$33.5M 1.02%
25,266
+8,570
+51% +$12.1M
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.73B
$33.2M 1.01%
+1,484,227
New +$33.5M
WAT icon
38
Waters Corp
WAT
$39.2B
$32.1M 0.98%
113,089
+18,592
+20% +$5.08M
DXCM icon
39
CALL
DexCom
DXCM
$32.9B
$31.3M 0.96%
+348,800
New +$32.7M
GH icon
40
Guardant Health
GH
$21.4B
$31.2M 0.95%
204,344
-23,532
-10% -$3.56M
ARKK icon
41
PUT
ARK Innovation ETF
ARKK
$6.06B
$31M 0.95%
+258,700
New +$35M
PODD icon
42
Insulet
PODD
$11.5B
$30.9M 0.94%
+118,382
New +$31.7M
BFLY icon
43
Butterfly Network
BFLY
$2.32B
$30.8M 0.94%
+1,828,311
New +$36.2M
DVAX
44
DELISTED
Dynavax Technologies
DVAX
$29.4M 0.9%
2,990,770
+53,780
+2% +$443K
THC icon
45
Tenet Healthcare
THC
$20.2B
$29.3M 0.89%
563,444
-422,575
-43% -$21.4M
BIIB icon
46
Biogen
BIIB
$30.6B
$28.5M 0.87%
102,034
-12,570
-11% -$3.39M
NTLA icon
47
Intellia Therapeutics
NTLA
$1.56B
$22.8M 0.7%
+284,101
New +$19.1M
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$21.5M 0.66%
+178,846
New +$20.3M
ALLO icon
49
Allogene Therapeutics
ALLO
$652M
$20.8M 0.64%
+590,378
New +$19.9M
DXCM icon
50
DexCom
DXCM
$32.9B
$20.3M 0.62%
+225,768
New +$21.2M
1
2
3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q1 2021 Portfolio in Review

As of Q1 2021, PFM Health Sciences held 113 positions worth $3.27B, up 15% from $2.84B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

PFM Health Sciences deployed $259M of net new capital in Q1 2021, opening 28 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,055,510 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Penumbra, an estimated $32.4M trimmed.

  • PFM Health Sciences's largest Q1 2021 buy was Neurocrine Biosciences: 1,055,510 shares worth $103M.
  • PFM Health Sciences added most to Eli Lilly in Q1 2021, an estimated $34.2M increase.
  • PFM Health Sciences's biggest Q1 2021 reduction was Penumbra, cutting an estimated $32.4M.
  • PFM Health Sciences fully exited Elevance Health in Q1 2021, selling an estimated $52.7M.
  • PFM Health Sciences's ten largest holdings make up 37% of its $3.27B portfolio in Q1 2021.
  • PFM Health Sciences opened 28 new positions and closed 27 in Q1 2021.
  • PFM Health Sciences's portfolio value rose 15% quarter-over-quarter to $3.27B.

Based on PFM Health Sciences's 13F filing for Q1 2021, filed 17 May 2021.